Study of Dotatate Imaging in Breast Cancer
Recruiting
This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.
Gender:
Female
Ages:
18 years and above
Locations: Hoag Memorial Hospital Presbyterian, Irvine, California
Conditions: Breast Cancer Stage IV
Observational Study to Assess the Reliability and Validity of the MLYMT
Recruiting
This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT). Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT at multiple luminance levels and (ii) reliability and content validity of MLYMT.
Gender:
All
Ages:
18 years and above
Locations: Nanoscope Clinical Site, Beverly Hills, California +6 locations
Conditions: Retinitis Pigmentosa, Retinal Dystrophy
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating sy... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Locations: Irvine Clinical Research /ID# 250030, Irvine, California +11 locations
Conditions: Alzheimer's Disease (AD)
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses of RO7121932 in participants with multiple sclerosis (MS)
Gender:
All
Ages:
Between 18 years and 65 years
Locations: Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California +22 locations
Conditions: Multiple Sclerosis
NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
Recruiting
Background: Replacing a valve in the heart can save many people s lives. The procedure is called transcatheter aortic valve replacement (TAVR). In rare cases, a flap of tissue called a leaflet can shift during TAVR; the leaflet may block blood flow to the coronary arteries, which supply blood to the heart muscle. About 50% of people who experience this problem will die. To reduce this risk, doctors will cut this leaflet during TAVR. But the tools used to cut the leaflet were originally designed... Read More
Gender:
All
Ages:
Between 21 years and 109 years
Locations: California Pacific Med Ctr, San Francisco, California +9 locations
Conditions: Valvular Heart Disease, Aortic Valve Failure
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Recruiting
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the stud... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Locations: Om Research LLC, Lancaster, California +12 locations
Conditions: Primary Sclerosing Cholangitis
Siplizumab in T1DM
Recruiting
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. Blood samples f... Read More
Gender:
All
Ages:
Between 8 years and 45 years
Locations: UCSF School of Medicine: UCSF Diabetes Clinic, San Francisco, California +19 locations
Conditions: Type 1 Diabetes Mellitus
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Recruiting
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests loo... Read More
Gender:
All
Ages:
All
Locations: PCR Oncology, Arroyo Grande, California +133 locations
Conditions: Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Recruiting
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
Gender:
All
Ages:
18 years and above
Locations: Jonsson Comprehensive Cancer Center, Santa Monica, California +9 locations
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed. Telisotuzumab vedotin is an investigational dr... Read More
Gender:
All
Ages:
18 years and above
Locations: Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671, Los Alamitos, California +24 locations
Conditions: Non Small Cell Lung Cancer
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
Recruiting
A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
Gender:
All
Ages:
Between 18 years and 55 years
Locations: Research Site, Glendale, California +1 locations
Conditions: Healthy Participants
Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer
Recruiting
The PIK3CA gene is frequently mutated in breast cancer, leading to disease aggressiveness and patient mortality. Alpelisib, a small molecule that inhibits the activity of the PIK3CA gene product PI3Kα, has demonstrated clinical benefit in cancer patients with this gene mutation. However, hyperglycemia, an on-target toxicity associated with alpelisib that leads to hyperinsulinemia, limits the drug's clinical efficacy and induces high grade hyperglycemia in patients with baseline metabolic dysfunc... Read More
Gender:
All
Ages:
18 years and above
Locations: Loma Linda University Cancer Center, Loma Linda, California +5 locations
Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer